178 related articles for article (PubMed ID: 34035415)
121. The Molecular Role of IL-35 in Non-Small Cell Lung Cancer.
Hao Y; Dong H; Li W; Lv X; Shi B; Gao P
Front Oncol; 2022; 12():874823. PubMed ID: 35719927
[TBL] [Abstract][Full Text] [Related]
122. Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC.
Oitabén A; Fonseca P; Villanueva MJ; García-Benito C; López-López A; Garrido-Fernández A; González-Ojea C; Juaneda-Magdalena L; Lázaro ME; Martínez-Fernández M
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681606
[TBL] [Abstract][Full Text] [Related]
123. Perioperative Systemic Inflammation in Lung Cancer Surgery.
Furák J; Németh T; Lantos J; Fabó C; Géczi T; Zombori-Tóth N; Paróczai D; Szántó Z; Szabó Z
Front Surg; 2022; 9():883322. PubMed ID: 35669251
[TBL] [Abstract][Full Text] [Related]
124. Reduced FEV
Shen YL; Shen CI; Chiang CL; Huang HC; Chou KT; Chiu CH; Chen YM; Luo YH
Front Med (Lausanne); 2022; 9():860733. PubMed ID: 35391883
[TBL] [Abstract][Full Text] [Related]
125. Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy.
Smith PL; Piadel K; Dalgleish AG
Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960140
[TBL] [Abstract][Full Text] [Related]
126. Whole blood viscosity is associated with extrahepatic metastases and survival in patients with hepatocellular carcinoma.
Han JW; Sung PS; Jang JW; Choi JY; Yoon SK
PLoS One; 2021; 16(12):e0260311. PubMed ID: 34855786
[TBL] [Abstract][Full Text] [Related]
127. Promising predictors of checkpoint inhibitor response in NSCLC.
Alex F; Alfredo A
Expert Rev Anticancer Ther; 2020 Nov; 20(11):931-937. PubMed ID: 32870120
[TBL] [Abstract][Full Text] [Related]
128. Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study.
Kauffmann-Guerrero D; Kahnert K; Kiefl R; Sellmer L; Walter J; Behr J; Tufman A
Sci Rep; 2021 May; 11(1):10919. PubMed ID: 34035415
[TBL] [Abstract][Full Text] [Related]
129. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
130. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
131. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
132. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
133. Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study).
Takamori S; Ohba T; Shimokawa M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Seto T; Takenoyama M
PLoS One; 2021; 16(10):e0258616. PubMed ID: 34679113
[TBL] [Abstract][Full Text] [Related]
134. Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer.
Lim JU; Yoon HK
Cytokine; 2021 Feb; 138():155363. PubMed ID: 33264749
[TBL] [Abstract][Full Text] [Related]
135. Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy.
Viñal D; Gutierrez-Sainz L; Martinez D; Garcia-Cuesta JA; Pedregosa J; Villamayor J; Ostios L; Sanchez-Cabrero D; Higuera O; Pinto A; Rodriguez-Salas N; Espinosa E; de Castro J; Feliu J
Clin Transl Oncol; 2021 Jun; 23(6):1185-1192. PubMed ID: 33226553
[TBL] [Abstract][Full Text] [Related]
136.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
137.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
138.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
139.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
140.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
